Cero Therapeutics Holdings, Inc.
CERO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001870404
No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCEROW
Q4 2022 vs. Q3 2022
How the institutions holding Cero Therapeutics Holdings, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 66 | 46 | −20 |
| Shares | 15.2M | 9.85M | −5.31M (−35.0%) |
| Value | $153.0M | $101.1M | −$51.9M (−33.9%) |
New holders (10)
Institutions that held Cero Therapeutics Holdings, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Beryl Capital Management LLC | 542,376 | $5.57M | 2.24% |
| Exos TFP Holdings LLC | 125,771 | $1.29M | 0.36% |
| Difesa Capital Management, LP | 125,000 | $1.29M | 1.00% |
| Atlas Merchant Capital LLC | 80,000 | $820.8K | 0.14% |
| Walleye Capital LLC | 47,936 | $492.3K | 0.01% |
| Silver Rock Financial LP | 46,243 | $474.9K | 0.15% |
| Gritstone Asset Management LLC | 34,026 | $349.5K | 0.45% |
| Walleye Trading LLC | 26,964 | $276.9K | 0.01% |
| Susquehanna International Group, LLP | 18,699 | $192.6K | 0.00% |
| K2 Principal Fund, L.P. | 12,124 | $124.4K | 0.03% |
Sold out (30)
Institutions that held Cero Therapeutics Holdings, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.